Mammography and BHRT: What Patients Need to Know About Screening, Dense Breast Tissue, and Guidelines
For women considering or currently using bioidentical hormone replacement therapy, mammography raises important and sometimes confusing questions. Does BHRT affect mammogram results? Does estrogen increase breast density? When should you screen, and what supplemental imaging might be appropriate? Getting accurate answers to these questions allows you to engage in screening proactively and without unnecessary fear — while ensuring you have the best possible protection against breast cancer.
What Mammography Detects
Mammography uses low-dose X-rays to image breast tissue, looking for masses, calcifications, and architectural distortions that may indicate cancer or precancerous changes. It is the most widely studied and validated breast cancer screening tool available, with decades of evidence supporting its ability to reduce breast cancer mortality through early detection.
A mammogram produces two types of tissue: radiolucent (fatty) tissue, which appears dark on the image, and radiodense tissue — glandular and fibrous tissue — which appears white. Cancer also appears white. When breast tissue is dense, it can obscure cancers that might otherwise be visible, reducing the sensitivity of mammography as a screening tool.
BHRT and Breast Density
Estrogen and progesterone stimulate glandular breast tissue, which contributes to radiographic breast density. Women on combined estrogen-progestin hormone therapy have been found in multiple studies to have greater mammographic density than non-users. This is not a new risk factor created by BHRT — it is the same hormonal sensitivity to estrogen that premenopausal women have naturally — but it is clinically relevant because increased density can reduce mammogram sensitivity.
The effect on density appears to be more pronounced with combined estrogen-progestin formulations than with estrogen alone, and there is emerging evidence that bioidentical progesterone may have less impact on breast density than synthetic progestins. However, even with bioidentical BHRT, some increase in breast density is possible, and women on BHRT should be aware that their radiologist and mammography provider should know they are taking hormone therapy at the time of their scan.
Increased breast density on mammography does not automatically mean your result is abnormal — it is a reporting category (categorized as heterogeneously dense or extremely dense) that informs screening recommendations, not a pathological finding.
Dense Breast Tissue and Supplemental Screening
Women with dense breasts have two distinct considerations: reduced mammogram sensitivity (the dense tissue can mask cancers) and modestly elevated breast cancer risk independent of imaging (dense breasts are themselves a risk factor, not just an imaging challenge). For women with heterogeneously or extremely dense breast tissue — which accounts for approximately 40 percent of women in the United States — supplemental screening is often recommended.
Digital breast tomosynthesis (3D mammography) improves cancer detection rates in dense breasts compared to traditional 2D mammography and has become the standard of care at most facilities. Breast ultrasound can identify cancers that are not visible on mammogram in dense tissue and is often used as a supplemental screen. Breast MRI with contrast provides the highest sensitivity of any imaging modality and is recommended for women with high lifetime risk (above 20 percent) — including those with BRCA1/2 mutations, strong family history, or prior chest radiation.
If you are on BHRT and have dense breast tissue, discussing supplemental screening with your gynecologist or radiologist is appropriate. Informed decision-making about screening frequency and modality is not cause for alarm — it is cause for engagement.
Current Screening Guidelines
Screening guidelines vary somewhat between organizations, which creates understandable confusion. The American Cancer Society recommends annual mammography beginning at age 45, with the option to start at 40, continuing as long as a woman is in good health. The U.S. Preventive Services Task Force (2024 updated guidelines) recommends biennial mammography beginning at age 40 for average-risk women.
Women at elevated risk should be screened more frequently and may need to start earlier. Risk factors for breast cancer include: first-degree relative with breast cancer, personal history of atypical hyperplasia on prior biopsy, known BRCA1/2 or other high-risk gene variant, prior chest radiation between ages 10–30, and high breast density combined with other risk factors. Any woman with one or more of these factors should discuss a personalized screening plan with her physician.
Timing Mammography Around BHRT
Some clinicians recommend scheduling mammography before initiating BHRT to obtain a baseline assessment of breast density and tissue characteristics. This baseline can be useful for comparison in future years. For women already on BHRT, continuing their screening schedule without interrupting therapy is appropriate — there is no evidence that stopping hormone therapy shortly before a mammogram improves results in a clinically meaningful way, and the hormonal disruption is not warranted.
Always inform your mammography technologist and radiologist that you are on hormone therapy so your images are interpreted in the appropriate clinical context.
Kenton Bruice, M.D. takes a thorough, safety-conscious approach to BHRT, including integrating appropriate screening recommendations into each patient's care plan. If you have questions about mammography, breast density, and BHRT, schedule a consultation at his Denver, Aspen, or St. Louis practice for personalized guidance grounded in current evidence.